作者
Jenny Lee, Richard Kefford, Matteo Carlino
发表日期
2016/6
来源
Immunotherapy
卷号
8
期号
6
页码范围
733-746
出版商
Future Medicine Ltd
简介
Anti-programmed death (PD)-1 antibodies have now become the standard of care for advanced melanoma, with two drugs gaining US FDA approval in recent years: nivolumab and pembrolizumab. Both have demonstrated significant activity and durable response with a manageable toxicity profile. Despite initial success, ongoing challenges include patient selection and predictors of response, innate resistance and optimizing combination strategies. In this overview, we take a closer look at the history and development of therapeutic targets to the PD-1/PD-ligand (L)1 pathway, clinical evidence, availability of biomarkers and their limitations in clinical practice and future strategies to improve treatment outcomes.
学术搜索中的文章
J Lee, R Kefford, M Carlino - Immunotherapy, 2016